Human epidermal growth factor 2 (HER2 or ErbB2) mutations in lung cancer are oncogenic drivers similar to epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers. Until recently, ErbB2-mutant lung cancers have generally been resistant to various targeted agents. However, a new wave of ErbB2-targeting drugs has shown promise for this subset. We highlight a case of a patient with an ErbB2-mutant lung cancer with an exon 20 YVMA insertion who had a good response to poziotinib and review the current literature on the methods of testing for ErbB2 mutations and the efficacy of various known and emerging targeted agents.
- ErbB2 mutations
- Exon 20 YVMA insertion
- Non-small cell lung cancer (NSCLC)
ASJC Scopus subject areas
- Cancer Research
- Pharmacology (medical)
- Anesthesiology and Pain Medicine